

Sasja F Mulder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6256498/publications.pdf>

Version: 2024-02-01

26
papers

455
citations

933447

10
h-index

713466

21
g-index

26
all docs

26
docs citations

26
times ranked

836
citing authors

#	ARTICLE	IF	CITATIONS
1	Exposureâ€toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer. <i>International Journal of Cancer</i> , 2022, 150, 308-316.	5.1	8
2	Exposureâ€response analyses of cabozantinib in patients with metastatic renal cell cancer. <i>BMC Cancer</i> , 2022, 22, 228.	2.6	11
3	Roles of general practitioners in shared decisionâ€making for patients with cancer: A qualitative study. <i>European Journal of Cancer Care</i> , 2022, 31, e13594.	1.5	3
4	Cardiovascular disease in testicular cancer survivors: Identification of risk factors and impact on quality of life.. <i>Journal of Clinical Oncology</i> , 2022, 40, 12070-12070.	1.6	1
5	Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 274.e1-274.e16.	1.9	12
6	The relationship between sunitinib exposure and both efficacy and toxicity in realâ€world patients with renal cell carcinoma and gastrointestinal stromal tumour. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 326-335.	2.4	18
7	Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. <i>BMC Gastroenterology</i> , 2021, 21, 67.	2.0	2
8	Lost in third space: altered tyrosine-kinase inhibitor pharmacokinetics in a patient with malignant ascites. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, , 1.	2.3	2
9	Hospital-specific probability of cystectomy affects survival from muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 935.e9-935.e16.	1.6	2
10	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020, 25, e1509-e1515.	3.7	10
11	The Effect of Using Pazopanib With Food vs. Fasted on Pharmacokinetics, Patient Safety, and Preference (<scp>DIET</scp> Study). <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1076-1082.	4.7	26
12	A reduced pazopanib dose with food: Is it more patient-friendly and does it reduce drug costs?. <i>Journal of Clinical Oncology</i> , 2019, 37, 4564-4564.	1.6	2
13	Positron Emission Tomography/Computed Tomography with 89Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. <i>European Urology</i> , 2018, 74, 257-260.	1.9	65
14	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. <i>Targeted Oncology</i> , 2018, 13, 641-648.	3.6	10
15	Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1062-1062.	1.6	0
16	Real world experience and biomarkers of nivolumab in dutch advanced renal-cell carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4572-4572.	1.6	0
17	Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2195-2204.	2.4	61
18	Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa?. <i>Acta OncolÃ³gica</i> , 2016, 55, 444-448.	1.8	6

#	ARTICLE	IF	CITATIONS
19	Phase 2 Study of Lutetium 177 ^{â€} Labeled Anti ^{â€} Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 767-770.	1.9	57
20	Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. <i>Anticancer Research</i> , 2015, 35, 5601-6.	1.1	2
21	Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. <i>Frontiers in Immunology</i> , 2014, 5, 191.	4.8	71
22	Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study. <i>BMC Cancer</i> , 2014, 14, 219.	2.6	53
23	Humoral and cellular immune response after influenza vaccination in patients with postcancer fatigue and patients with chronic fatigue syndrome.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9070-9070.	1.6	0
24	The complexity of sunitinib dosing in renal cell cancer patients. <i>Translational Andrology and Urology</i> , 2012, 1, 194-6.	1.4	0
25	Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination. <i>Clinical Cancer Research</i> , 2011, 17, 4541-4549.	7.0	28
26	Do the Results of the New Trials Change the Standard Treatment of Metastatic Renal Cell Cancer?. <i>Oncology Research and Treatment</i> , 2007, 30, 260-264.	1.2	5